Published in Am J Hypertens on April 02, 2013
Optimal renin-angiotensin system blockade-wishful thinking? Nat Rev Cardiol (2013) 1.08
Physiology of the Renal Interstitium. Clin J Am Soc Nephrol (2015) 0.84
Humid heat exposure induced oxidative stress and apoptosis in cardiomyocytes through the angiotensin II signaling pathway. Heart Vessels (2014) 0.78
Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort. J Clin Hypertens (Greenwich) (2014) 0.76
When blockade of the renin-angiotensin system becomes a two-edged sword. Am J Hypertens (2013) 0.75
John H. Laragh, MD: clinician-scientist. Am J Hypertens (2014) 0.75
Renin Angiotensin Aldosterone Inhibition in the Treatment of Cardiovascular Disease. Pharmacol Res (2017) 0.75
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ (2011) 6.19
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA (2007) 5.02
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA (2004) 4.71
Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation (2003) 3.76
A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ (2009) 3.65
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care (2007) 3.62
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ (2008) 3.56
Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2004) 3.26
Sodium intake and mortality in the NHANES II follow-up study. Am J Med (2006) 3.24
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10
Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2002) 3.05
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation (2008) 2.85
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet (2004) 2.78
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology (2013) 2.61
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens (2007) 2.43
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Rosiglitazone and cardiovascular risk. N Engl J Med (2007) 2.41
Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med (2007) 2.41
Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2003) 2.40
COX-2 inhibitors--lessons in drug safety. N Engl J Med (2005) 2.39
Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med (2010) 2.36
Recent trials in hypertension: compelling science or commercial speech? JAMA (2006) 2.30
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes (2011) 2.29
The safety risks of innovation: the FDA's Expedited Drug Development Pathway. JAMA (2012) 2.28
ALLHAT: setting the record straight. Ann Intern Med (2004) 2.19
From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol (2004) 2.16
Differences in medical care and disease outcomes among black and white women with heart disease. Circulation (2003) 2.16
Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ (2013) 2.06
The necessity for clinical reasoning in the era of evidence-based medicine. Mayo Clin Proc (2013) 2.06
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Lead editorial: trials - using the opportunities of electronic publishing to improve the reporting of randomised trials. Trials (2006) 1.98
Age as a modifiable risk factor for cardiovascular disease. Lancet (2008) 1.94
Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA (2004) 1.85
Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension (2006) 1.82
Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III). J Gen Intern Med (2008) 1.79
Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst (2006) 1.70
A call for higher standards of evidence for dietary guidelines. Am J Prev Med (2008) 1.69
Effect of physician volume on the relationship between hospital volume and mortality during primary angioplasty. J Am Coll Cardiol (2009) 1.67
Suicidal behavior and depression in smoking cessation treatments. PLoS One (2011) 1.65
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med (2010) 1.64
Acute myocardial infarction hospitalization in the United States, 1979 to 2005. Am J Med (2010) 1.63
Varenicline and suicide. Risk of psychiatric side effects with varenicline. BMJ (2009) 1.63
Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. Am J Hypertens (2011) 1.60
The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med (2007) 1.60
Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA (2004) 1.60
Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother (2010) 1.59
Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ (2010) 1.58
Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med (2002) 1.56
Hypertension control at physicians' offices in the United States. Am J Hypertens (2008) 1.56
Pressor responses to antihypertensive drug types. Am J Hypertens (2010) 1.56
Renal dysfunction and ischemic heart disease mortality in a hypertensive population. J Hypertens (2005) 1.55
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials (2012) 1.54
Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatr Soc (2005) 1.54
Is high pulse pressure a marker of preclinical cardiovascular disease? Hypertension (2005) 1.53
Why guideline-making requires reform. JAMA (2009) 1.52
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Parecoxib, valdecoxib, and cardiovascular risk. Circulation (2005) 1.51
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol (2010) 1.47
Tiotropium and the risk of death in COPD. N Engl J Med (2014) 1.46
Renin-guided treatment of hypertension: time for action. Am J Hypertens (2010) 1.46
Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens (2002) 1.45
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart (2008) 1.44
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med (2004) 1.43
The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc (2004) 1.38
Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int (2002) 1.35
Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience. Contemp Clin Trials (2006) 1.29
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Gen Intern Med (2008) 1.28
Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens (2009) 1.28
Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens (2011) 1.27
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials (2011) 1.27
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol (2010) 1.24
Blood-pressure-related disease is a global health priority. Lancet (2008) 1.22
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol (2008) 1.21
Prescription drugs associated with reports of violence towards others. PLoS One (2010) 1.21
Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation (2002) 1.18
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. Am Heart J (2012) 1.17
Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.15
Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol (2005) 1.15
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.14
The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc Med (2012) 1.13
Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study. J Clin Endocrinol Metab (2011) 1.12